Diffuse Astrocytic and Oligodendroglial Tumors
  • Serge Weis
  • Michael Sonnberger
  • Andreas Dunzinger
  • Eva Voglmayr
  • Martin Aichholzer
  • Raimund Kleiser
  • Peter Strasser


Glioblastoma (GBM) is a high-grade glioma with predominantly astrocytic differentiation; featuring nuclear atypia, cellular pleomorphism (in most cases), mitotic activity, and typically a diffuse growth pattern, as well as microvascular proliferation and/or necrosis, and which lacks mutations in the IDH genes.

GBM is the most frequent tumor of the CNS affecting predominantly persons between 40-80 years of age. All regions of the brain and spinal cord are susceptible; a preferential involvement of the telencephalon is noted with a characteristic involvement of the white matter.

On imaging, GBM presents as an irregular, heterogeneous, ring enhancing mass of variable size with central necrosis and surrounding vasogenic edema. GBMs are normally FDG-avid. Results obtained for MET-PET are similar to FET-PET enabling non-invasive tumor grading. Sensitivity of FET - PET for glioblastoma is about 95% (gliomatosis cerebri can be false negative).

GBM is a large tumor which involves several lobes. The tumor is usually not sharply demarcated presenting with a broad and diffuse zone of infiltration. Tumors spread to the contralateral hemisphere through the corpus callosum displaying a symmetrical tumor growth into both hemispheres, i.e. butterfly GBM.

GBM shows a high diversity of cell forms (thus, the former term of “glioblastoma multiforme”) which include high density of small, poorly differentiated cells with marked polymorphism of tumor cells including multinucleated giant cells, anaplastic cells displaying astrocytic features, atypical mitoses, vascular endothelial cell proliferation. Typical tumor necroses, i.e. palisading with cells arranged side by side in rows and their processes directed towards a central area of necrosis and large areas of necroses.

Genome-wide analyses revealed that the TP53 (tumor protein 53) pathway, the RTK (receptor tyrosine kinase)/RAS/PI3K (phosphoinositide 3-kinase) pathway, both involved in the regulation of cellular growth, apoptosis and proliferation, and the RB1 (retinoblastoma) pathway, controlling the G1 to S phase transition in the cell cycle are affected by genetic aberrations in GBM.

Mutations of IDH1 involved in cytosolic NADPH production at codon 132 are found in secondary GBM while IDH1 wildtype is characteristic for primary GBM. Mutations in the IDH2 gene at chromosome position 15q26.1, encoding the mitochondrial isoenzyme isocitrate dehydrogenase 2 (IDH2), are found at a considerably lower frequency. Further mutations of the TERT promoter and ATRX, mutations affecting oncogenes/tumor suppressor genes and chromosomal aberrations are described. Primary and secondary glioblastomas can be characterized on genetic grounds. The molecular classification of GBM distinguishes four distinct subtypes, i.e. proneural, neural, classical, and mesenchymal. Further changes include changes in DNA methylation (especially of the MGMT gene), microRNAs and gene expression.

State of the art therapy is given by the STUPP scheme including after the surgical intervention focal radiation therapy (RT) (total of 60 Gy delivered as 30 sessions with 2 Gy dose for a duration of 6 weeks) and temozolomide (TMZ). Mean survival is around 18 months with a range between 2 and 92 months. Prognostic factors include among others age of the patient, Karnofsky performance score, amount of resected tumor tissue, MGMT methylation status (methylated promotor → better response to TMZ → better overall survival), IDH-1 mutation status (mutation → better overall survival), polymorphisms in genes including EGFR, TP53, carcinogen-metabolizing gene, immune function (e.g. interleukin-4), DNA repair, telomerase hTERT, and microRNA expression.

Selected References

  1. Aldape K, Zadeh G, Mansouri S, Reifenberger G, von Deimling A (2015) Glioblastoma: pathology, molecular mechanisms and markers. Acta Neuropathol 129(6):829–848. Scholar
  2. Alfardus H, McIntyre A, Smith S (2017) MicroRNA regulation of glycolytic metabolism in glioblastoma. BioMed Res Int 2017:9157370. Scholar
  3. Anil R, Colen RR (2016) Imaging genomics in glioblastoma multiforme: a predictive tool for patients prognosis, survival, and outcome. Magn Reson Imaging Clin N Am 24(4):731–740. Scholar
  4. Areeb Z, Stylli SS, Koldej R, Ritchie DS, Siegal T, Morokoff AP, Kaye AH, Luwor RB (2015) MicroRNA as potential biomarkers in glioblastoma. J Neurooncol 125(2):237–248. Scholar
  5. Auffinger B, Spencer D, Pytel P, Ahmed AU, Lesniak MS (2015) The role of glioma stem cells in chemotherapy resistance and glioblastoma multiforme recurrence. Expert Rev Neurother 15(7):741–752. Scholar
  6. Bleeker FE, Molenaar RJ, Leenstra S (2012) Recent advances in the molecular understanding of glioblastoma. J Neurooncol 108(1):11–27. Epub 12012 Jan 11020.Google Scholar
  7. Bredel M, Scholtens DM, Harsh GR, Bredel C, Chandler JP, Renfrow JJ, Yadav AK, Vogel H, Scheck AC, Tibshirani R, Sikic BI (2009) A network model of a cooperative genetic landscape in brain tumors. JAMA 302(3):261–275. Scholar
  8. Chinot OL, Wick W, Mason W, Henriksson R, Saran F, Nishikawa R, Carpentier AF, Hoang-Xuan K, Kavan P, Cernea D, Brandes AA, Hilton M, Abrey L, Cloughesy T (2014) Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med 370(8):709–722. Scholar
  9. Colman H, Zhang L, Sulman EP, McDonald JM, Shooshtari NL, Rivera A, Popoff S, Nutt CL, Louis DN, Cairncross JG, Gilbert MR, Phillips HS, Mehta MP, Chakravarti A, Pelloski CE, Bhat K, Feuerstein BG, Jenkins RB, Aldape K (2010) A multigene predictor of outcome in glioblastoma. Neuro Oncol 12(1):49–57. Epub 2009 Oct 1020Google Scholar
  10. Corso CD, Bindra RS, Mehta MP (2017) The role of radiation in treating glioblastoma: here to stay. J Neurooncol 134(3):479–485. Scholar
  11. Crespo I, Vital AL, Gonzalez-Tablas M, Patino Mdel C, Otero A, Lopes MC, de Oliveira C, Domingues P, Orfao A, Tabernero MD (2015) Molecular and genomic alterations in glioblastoma multiforme. Am J Pathol 185(7):1820–1833. Scholar
  12. de Tayrac M, Aubry M, Saikali S, Etcheverry A, Surbled C, Guenot F, Galibert MD, Hamlat A, Lesimple T, Quillien V, Menei P, Mosser J (2011) A 4-gene signature associated with clinical outcome in high-grade gliomas. Clin Cancer Res 17(2):317–327. Epub 2011 Jan 1111Google Scholar
  13. Delgado-Lopez PD, Corrales-Garcia EM (2016) Survival in glioblastoma: a review on the impact of treatment modalities. Clin Transl Oncol 18(11):1062–1071. Scholar
  14. Devaux BC, O’Fallon JR, Kelly PJ (1993) Resection, biopsy, and survival in malignant glial neoplasms. A retrospective study of clinical parameters, therapy, and outcome. J Neurosurg 78(5):767–775. Scholar
  15. Di Costanzo A, Scarabino T, Trojsi F, Giannatempo GM, Popolizio T, Catapano D, Bonavita S, Maggialetti N, Tosetti M, Salvolini U, d’Angelo VA, Tedeschi G (2006a) Multiparametric 3T MR approach to the assessment of cerebral gliomas: tumor extent and malignancy. Neuroradiology 48(9):622–631. Scholar
  16. Di Costanzo A, Trojsi F, Giannatempo GM, Vuolo L, Popolizio T, Catapano D, Bonavita S, d'Angelo VA, Tedeschi G, Scarabino T (2006b) Spectroscopic, diffusion and perfusion magnetic resonance imaging at 3.0 Tesla in the delineation of glioblastomas: preliminary results. J Exp Clin Cancer Res 25(3):383–390Google Scholar
  17. Diaz RJ, Ali S, Qadir MG, De La Fuente MI, Ivan ME, Komotar RJ (2017) The role of bevacizumab in the treatment of glioblastoma. J Neurooncol 133(3):455–467. Scholar
  18. Dunn GP, Rinne ML, Wykosky J, Genovese G, Quayle SN, Dunn IF, Agarwalla PK, Chheda MG, Campos B, Wang A, Brennan C, Ligon KL, Furnari F, Cavenee WK, Depinho RA, Chin L, Hahn WC (2012) Emerging insights into the molecular and cellular basis of glioblastoma. Genes Dev 26(8):756–784. Scholar
  19. Ellison DW, Kleinschmidt-DeMasters BK, Park S-H (2016) Epithelioid glioblastoma. In: Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (eds) WHO classification of tumours of the central nervous system, revised 4th ed. IARC, Lyon, pp 50–51Google Scholar
  20. Franceschi E, Minichillo S, Brandes AA (2017) Pharmacotherapy of glioblastoma: established treatments and emerging concepts. CNS drugs 31(8):675–684. Scholar
  21. Gilbert MR, Dignam JJ, Armstrong TS, Wefel JS, Blumenthal DT, Vogelbaum MA, Colman H, Chakravarti A, Pugh S, Won M, Jeraj R, Brown PD, Jaeckle KA, Schiff D, Stieber VW, Brachman DG, Werner-Wasik M, Tremont-Lukats IW, Sulman EP, Aldape KD, Curran WJ Jr, Mehta MP (2014) A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med 370(8):699–708. Scholar
  22. Ho IAW, Shim WSN (2017) Contribution of the microenvironmental niche to glioblastoma heterogeneity. Biomed Res Int 2017:9634172. Scholar
  23. Killela PJ, Reitman ZJ, Jiao Y, Bettegowda C, Agrawal N, Diaz LA Jr, Friedman AH, Friedman H, Gallia GL, Giovanella BC, Grollman AP, He TC, He Y, Hruban RH, Jallo GI, Mandahl N, Meeker AK, Mertens F, Netto GJ, Rasheed BA, Riggins GJ, Rosenquist TA, Schiffman M, Shih IM, Theodorescu D, Torbenson MS, Velculescu VE, Wang TL, Wentzensen N, Wood LD, Zhang M, McLendon RE, Bigner DD, Kinzler KW, Vogelstein B, Papadopoulos N, Yan H (2013) TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc Natl Acad Sci U S A 110(15):6021–6026. Scholar
  24. Kleihues P, Burger PC, Aldape KD, Brat DJ, Biernat W, Bigner DD, Nakazato Y, Plate KH, Giangaspero F, von Deimling A, Ohgaki H, Cavenee WK (2007) Glioblastoma. In: Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (eds) WHO classification of tumours of the central nervous system, 4th edn. International Agency for Research on Cancer, Lyon, pp 33–46Google Scholar
  25. Kleihues P, Burger PC, Collins VP, Newcomb EW, Ohgaki H, Cavenee WK (2000) Glioblastoma. In: Kleihues P, Cavenee WK (eds) Pathology and genetics of tumours of the nervous system, 3rd edn. IARC Press, Lyon, pp 29–39Google Scholar
  26. Kleihues P, Burger PC, Scheithauer BW (1993) Histological typing of tumours of the central nervous system, 2nd edn. Springer, BerlinGoogle Scholar
  27. Lakin N, Rulach R, Nowicki S, Kurian KM (2017) Current advances in checkpoint inhibitors: lessons from non-central nervous system cancers and potential for glioblastoma. Front Oncol 7:141. Scholar
  28. Law M, Yang S, Wang H, Babb JS, Johnson G, Cha S, Knopp EA, Zagzag D (2003) Glioma grading: sensitivity, specificity, and predictive values of perfusion MR imaging and proton MR spectroscopic imaging compared with conventional MR imaging. AJNR Am J Neuroradiol 24(10):1989–1998Google Scholar
  29. Louis DN, Suvá ML, Burger PC, Perry A, Kleihues P, Aldape KD, Brat DJ, Biernat W, Bigner DD, Nakazato Y, Plate KH, Giangaspero F, Ohgaki H, Cavenee WK, Wick W, Barnholtz-Sloan J, Rosenblum MK, Hegi M, Stupp R, Hawkins C, Verhaak RGW, Ellison DW, von Deimling A (2016) Glioblastoma, IDH-wildtype. In: Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (eds) WHO classification of tumours of the central nervous system, revised 4th edn. IARC, Lyon, pp 28–45Google Scholar
  30. Marcelino Meliso F, Hubert CG, Favoretto Galante PA, Penalva LO (2017) RNA processing as an alternative route to attack glioblastoma. Human genetics. 136(9):1129–1141. Scholar
  31. Maxwell R, Jackson CM, Lim M (2017) Clinical trials investigating immune checkpoint blockade in glioblastoma. Curr Treat Options Oncol 18(8):51. Scholar
  32. Miranda A, Blanco-Prieto M, Sousa J, Pais A, Vitorino C (2017) Breaching barriers in glioblastoma. Part I: molecular pathways and novel treatment approaches. Int J Pharm 531(1):372–388. Scholar
  33. Moller HG, Rasmussen AP, Andersen HH, Johnsen KB, Henriksen M, Duroux M (2013) A systematic review of microRNA in glioblastoma multiforme: micro-modulators in the mesenchymal mode of migration and invasion. Mol Neurobiol 47(1):131–144. Epub 12012 Oct 12032Google Scholar
  34. Ohgaki H, Kleihues P, von Deimling A, Louis DN, Reifenberger G, Yan H, Weller M (2016) Glioblastoma, IDH-mutant. In: Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (eds) WHO classification of tumours of the central nervous system, revised 4th edn. IARC, Lyon, pp 52–56Google Scholar
  35. Paldino MJ, Barboriak D, Desjardins A, Friedman HS, Vredenburgh JJ (2009) Repeatability of quantitative parameters derived from diffusion tensor imaging in patients with glioblastoma multiforme. J Magn Reson Imaging 29(5):1199–1205. Scholar
  36. Sahebjam S, Sharabi A, Lim M, Kesarwani P, Chinnaiyan P (2017) Immunotherapy and radiation in glioblastoma. J Neurooncol 134(3):531–539. Scholar
  37. Shea A, Harish V, Afzal Z, Chijioke J, Kedir H, Dusmatova S, Roy A, Ramalinga M, Harris B, Blancato J, Verma M, Kumar D (2016) MicroRNAs in glioblastoma multiforme pathogenesis and therapeutics. Cancer Med 5(8):1917–1946. Scholar
  38. Shiroishi MS, Boxerman JL, Pope WB (2015) Physiologic MRI for assessment of response to therapy and prognosis in glioblastoma. Neuro Oncol 18(4):467–478. Scholar
  39. Stavrovskaya AA, Shushanov SS, Rybalkina EY (2016) Problems of glioblastoma multiforme drug resistance. Biochem Biokhim 81(2):91–100. Scholar
  40. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO, European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups, National Cancer Institute of Canada Clinical Trials Group (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352(10):987–996.Google Scholar
  41. Stupp R, Hegi ME, van den Bent MJ, Mason WP, Weller M, Mirimanoff RO, Cairncross JG, European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups, National Cancer Institute of Canada Clinical Trials Group (2006) Changing paradigms—an update on the multidisciplinary management of malignant glioma. Oncologist 11(2):165–180.Google Scholar
  42. Tipping M, Eickhoff J, Ian Robins H (2017) Clinical outcomes in recurrent glioblastoma with bevacizumab therapy: an analysis of the literature. J Clin Neurosci 44:101–106. Scholar
  43. Touat M, Duran-Pena A, Alentorn A, Lacroix L, Massard C, Idbaih A (2015) Emerging circulating biomarkers in glioblastoma: promises and challenges. Expert Rev Mol Diagn 15(10):1311–1323. Scholar
  44. Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, Miller CR, Ding L, Golub T, Mesirov JP, Alexe G, Lawrence M, O’Kelly M, Tamayo P, Weir BA, Gabrie S, Winckler W, Gupta S, Jakkula L, Feiler HS, Hodgson JG, James CD, Sarkaria JN, Brennan C, Kahn A, Spellman PT, Wilson RK, Speed TP, Gray JW, Meyerson M, Getz G, Perou CM, Hayes DN (2010) An integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR and NF1. Cancer Cell 17(1):98Google Scholar
  45. Watson LA, Goldberg H, Berube NG (2015) Emerging roles of ATRX in cancer. Epigenomics 7(8):1365–1378. Epub 2015 Dec 1368Google Scholar
  46. Zülch KJ (1979) Histological typing of tumours of the central nervous system. World Health Organization, GenevaGoogle Scholar

Copyright information

© Springer-Verlag GmbH Austria, part of Springer Nature 2019

Authors and Affiliations

  • Serge Weis
    • 1
  • Michael Sonnberger
    • 2
  • Andreas Dunzinger
    • 3
  • Eva Voglmayr
    • 2
  • Martin Aichholzer
    • 4
  • Raimund Kleiser
    • 2
  • Peter Strasser
    • 5
  1. 1.Division of Neuropathology, Neuromed CampusKepler University Hospital, Johannes Kepler UniversityLinzAustria
  2. 2.Department of Neuroradiology, Neuromed CampusKepler University Hospital, Johannes Kepler UniversityLinzAustria
  3. 3.Department of Neuro-Nuclear Medicine, Neuromed CampusKepler University Hospital, Johannes Kepler UniversityLinzAustria
  4. 4.Department of Neurosurgery, Neuromed CampusKepler University Hospital, Johannes Kepler UniversityLinzAustria
  5. 5.PMU University Institute for Medical & Chemical Laboratory DiagnosticsSalzburgAustria

Personalised recommendations